Nobiretic (Hydrochlorothiazide, Nebivolol)

Hydrochlorothiazide and Nebivolol, the active ingredients in Nobiretic, are a combination diuretic (thiazide) and beta‑blocker presented as an oral tablet for oral use. The product is indicated for the treatment of hypertension in adult patients. GNH USA supplies Nobiretic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nobiretic, a combination antihypertensive, is used to manage elevated blood pressure. - Hypertension: lowers systolic and diastolic pressure in patients with primary hypertension. - Essential hypertension: helps achieve target blood pressure when monotherapy is insufficient. - Secondary hypertension: may be employed as part of combination therapy for hypertension secondary to renal or endocrine disorders.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain often occurring early in therapy. - Increased urination: due to the diuretic component. - Fatigue: general tiredness or weakness.

Serious or Rare Side Effects: - Severe electrolyte imbalance: such as hypokalemia or hyponatremia. - Acute gout attacks: sudden joint pain due to uric acid changes. - Significant hypotension: dangerously low blood pressure. - Bronchospasm: airway constriction, particularly in susceptible individuals. - Allergic reactions: including rash, angioedema, or anaphylaxis.

Before initiating therapy, consider the following precautions: - Monitor electrolytes: regularly check serum potassium and sodium levels. - Assess renal function: evaluate kidney function prior to and during treatment. - Caution in diabetes: monitor blood glucose as the drug may affect glycemic control. - Avoid abrupt discontinuation: sudden stop can cause rebound hypertension. - Store at room temperature: keep in the original pack, protect from moisture and light.

Nobiretic may interact with several medicines.

Major Interactions (Avoid): - NSAIDs: may reduce diuretic efficacy and increase renal risk. - Other antihypertensives: can cause excessive hypotension. - Lithium: increased lithium levels and toxicity. - Potassium‑sparing diuretics: risk of hyperkalemia. - CYP2D6 inhibitors: elevate nebivolol plasma concentrations.

Moderate Interactions (Monitor Closely): - ACE inhibitors: enhanced renal effects, monitor kidney function. - Antidiabetic drugs: possible alteration of glucose control. - Warfarin: may affect INR, require monitoring. - Alcohol: can increase dizziness and hypotensive effects. - Antidepressants (SSRIs): may augment blood pressure lowering.